Tumor Immunotargeting Using Innovative Radionuclides

International Journal of Molecular Sciences

Françoise Kraeber-Bodéré¹  Caroline Rousseau¹  Caroline Bodet-Milin¹  Cຝric Mathieu²  François Guérard¹  Eric Frampas¹  Thomas Carlier¹  Nicolas Chouin³  Ferid Haddad⁴  Jean-François Chatal⁴  Alain Faivre-Chauvet¹  Michel Chérel¹  Jacques Barbet¹ 

[1] Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France; E-Mails:;Department of Nuclear Medicine, University Hospital, Nantes 44093, France; E-Mail:;AMAROC, ONIRIS, Nantes 44300, France; E-Mail:;Physics Department, Groupement d’Intérêt Public Arronax, Nantes 44817, France; E-Mails:

关键词: innovative radionuclides;    alpha particle-emitting radionuclides;    alpha-immunotherapy;    radioimmunotherapy;    immuno-PET;   

DOI  :  10.3390/ijms16023932

来源: mdpi

【 摘 要 】

This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.